SOLUBLE TUMOR-NECROSIS-FACTOR RECEPTORS P55 AND P75 IN THE URINE MONITOR DISEASE-ACTIVITY AND THE EFFICACY OF TREATMENT OF INFLAMMATORY BOWEL-DISEASE

被引：44

作者：

HADZISELIMOVIC, F

EMMONS, LR

GALLATI, H

机构：

[1] UNIV CLIN BASLE, CHILDRENS HOSP, DEPT GASTROENTEROL, BASEL, SWITZERLAND

[2] F HOFFMANN LA ROCHE & CO LTD, PHARMACEUT RES, CH-4002 BASEL, SWITZERLAND

来源：

GUT | 1995年 / 37卷 / 02期

关键词：

TUMOR NECROSIS FACTOR; INFLAMMATORY BOWEL DISEASE; URINE;

D O I：

10.1136/gut.37.2.260

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

The aim of the study was to discover if soluble tumour necrosis factor receptors (sTnF-R p55 and p75) in the urine of patients with inflammatory boWel disease (IBD) could be used to monitor the different stages of the activity of the diseases. Twenty five patients with either Crohn's disease or ulcerative colitis were followed up during a longterm study. The 16 patients who become acutely ill with either Crohn's disease or ulcerative colitis had significantly higher concentrations of sTNF-R p55 and p75 in their urine compared with those who were in remission, or those who were normal controls. There was a significant correlation between increased concentrations (>20 ng/ml) of both sTNF-R p55 and p75 in the urine and a high Crohn's disease activity index (CDAI) and colitis activity index (CAI). Therefore, determination of sTNF-R is a good non-invasive parameter that can be used to assess the activity of disease and the efficacy of treatment.

引用

页码：260 / 263

页数：4

共 14 条

[1] Beutler B., Cerami A., Tumor necrosis, cachexia, shock, and inflammation: A common mediator, Ann Rev Biochem, 57, pp. 505-518, (1988)
[2] Beutler B., Cerami A., The biology of cachectin/TNF - A primary mediator of the host response, Ann Rev Immunol, 7, pp. 625-655, (1989)
[3] Tracy K.J., Cerami A., Metabolic responses to cachectin/TNF: A brief review, Ann NY Acad Sci, 587, pp. 325-331, (1990)
[4] Tracy K.J., Wei H., Manogue K.R., Fong Y., Hesse D.G., Lowry S.F., Cachectin/tumor necrosis factor induces cachexia, anemia and inflammation, J Exp Med, 167, pp. 1211-1227, (1988)
[5] Fong Y., Maldawer L.L., Marano M.A., Wei H., Barber A., Manogue K.R., Et al., Chronic cachectin/TNF or IL-1 alpha induces cachexia with redistribution of body proteins, Am J Physiol, 256, (1989)
[6] Johnson R.A., Wadelow T.A., Caro J., Oliff A., Roodman G.D., Chronic exposure to tumor necrosis factor in vivo preferentially inhibits erythropoiesis in nude mice, Blood, 74, pp. 130-138, (1989)
[7] Tracy K.J., Morgello S., Koplin B., Fahley III T.J., Fox J., Alco A., Et al., Metabolic effects of cachectin/tumor necrosis factor are modified by site of production, J Clin Invest, 86, pp. 2014-2024, (1990)
[8] Hudson M., Gallati H., Ryff J.C., Pounder R.E., Wakefield A.J., Serum tumour necrosis factor (TNF) and soluble TNF receptors p55 and p75 in Crohn's disease, Gastroenterology, 104, SUPPL., (1993)
[9] Reinecker H.-C., Steffen M., Witthoeft T., Pflueger I., Schreiber S., MacDermott R.P., Et al., Enhanced secretion of tumour necrosis factor-alpha, IL-6, and IL-1β by isolated lamina propria mononuclear cells from patients with ulcerative colitis and Crohn's disease, Clin Exp Immunol, 94, pp. 174-181, (1993)
[10] Murch A.H., Braegger C.P., Walker-Smith J.A., Mac-Donald T.T., Location of tumour necrosis factor alpha by immunohistochemistry in chronic inflammatory bowel disease, Gut, 34, pp. 1705-1709, (1993)

← 1 2 →